(BERLIN, Germany and LONDON, England) 12 July, 2019 - Aladdin Healthcare Technologies SE (“Aladdin”), a leading developer of AI healthcare diagnostics and drug discovery applications, today announced it has entered into a memorandum of understanding (MOU) with Imperial Institute of Advanced Technology (IAAT).
IAAT has been established by a team of royal academicians and professors from Imperial College London and Royal Brompton Hospital. It is a new research and development institute engaging the international exchange and cooperation in science and technology, Chinese-European technology transfer, and research in medical imaging technology. It is also committed to bringing human resources, technologies, projects in the field of healthcare from Europe to China, and promoting them in China.
The MOU enables Aladdin to host and open its greater China office from a leading science park in Hangzhou China home to multiple unicorn technology companies. The MOU also acts as a prelude to a contractual partnership that will enable Aladdin to jointly develop AI healthcare applications, AI software toolkits for drug discovery, fast track Chinese Food and Drug Administration (CFDA) applications, commercial AI software distribution and access government funding with IAAT. This includes IAAT granting Aladdin access to both its China and International partners and healthcare contacts.
Aladdin places real significance on this future partnership as a further access point to the Chinese healthcare market and to further assist in the development and commercialisation of its AI applications.
Wade Menpes-Smith (Chairman)
End of Media Release